Hanlin Gao - 02 Sep 2026 Form 4 Insider Report for Fulgent Genetics, Inc. (FLGT)

Reporting relationship: Chief Scientific Officer
Issuer ticker: FLGT
Reported as of: 02 Sep 2026
Net transaction value: -$32,885
SEC form: 4
Accepted by SEC: 03 Sep 2026, 19:47:39 UTC
Prior SEC filing: 28 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Paul Kim as Attorney-in-Fact

Key filing fact

Hanlin Gao filed Form 4 for Fulgent Genetics, Inc. (FLGT) on 03 Sep 2026.

Key facts

This page summarizes Hanlin Gao's Form 4 filing for Fulgent Genetics, Inc. (FLGT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 19:47.

Change

Previous filing in this sequence was filed on 28 Aug 2026.
Current net transaction value: -$32,885.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001684532 Primary reporting owner

Gao Hanlin

Relationship: Chief Scientific Officer
Address: C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVENUE, EL MONTE
Signature: /s/ Paul Kim as Attorney-in-Fact
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FLGT transaction

Common Stock

Sale

Transaction value: $32,885
Shares: -1,673
Change %: -0.17%
Price: $19.66
Shares after: 986,117
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.

Footnote F2

The shares were sold in multiple transactions at prices ranging from $19.60 to $19.74, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.